Form 4: Fortress Biotech Director Dov Klein Acquires Shares of Restricted Stock

Director Dov Klein acquired 49,383 shares of restricted stock in Fortress Biotech, with vesting occurring over three years.

Summary

• On January 1, 2025, Dov Klein, a director of Fortress Biotech, acquired 49,383 shares of restricted stock.
• These shares were granted under the company's 2013 Stock Incentive Plan, as amended.
• The shares vest in three equal installments on January 1, 2026, 2027, and 2028, contingent upon continued service.
• Klein elected to defer 50% of these shares, receiving deferred share units instead, which are subject to the same vesting conditions.
• Vested deferred shares will be delivered in January following termination of service, or earlier upon death or change in control.
• Following the transaction, Klein's total holdings include 102,783 shares, including 75,346 shares underlying deferred restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of restricted stock aligns director interests with shareholders, which is generally viewed favorably. The vesting schedule promotes long-term commitment.

Positives

• The grant of restricted stock to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• The value of the restricted stock is tied to the performance of Fortress Biotech's stock, which can be volatile.
• The director's continued service is required for the shares to fully vest.

Future Outlook

The director's compensation is tied to the company's stock performance over the next three years, incentivizing value creation.

Industry Context

Granting restricted stock is a common practice in the biotech industry to align management and director interests with those of shareholders, incentivizing long-term value creation.

Comparison to Industry Standards

• Many biotech companies use stock-based compensation, including restricted stock units (RSUs) and stock options, to attract and retain talent.
• Companies like Amgen, Gilead Sciences, and Biogen regularly grant equity awards to their executives and directors.
• The vesting schedules and terms of these awards vary, but a three-year vesting period is fairly standard.

Stakeholder Impact

• Shareholders: Aligns director's interests with shareholder value.
• Employees: May boost morale knowing leadership is invested in the company's success.

Key Dates